Altering β-cell number through stable alteration of miR-21 and miR-34a expression
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
AIM: An insufficient functional β-cell mass is a prerequisite to develop diabetes. Thus, means to protect or restore β-cell mass are important goals in diabetes research. Inflammation and proinflammatory cytokines play important roles in β-cell dysfunction and death, and recent data show that 2 miRNAs, miR-21 and miR-34a, may be involved in mediating cytokine-induced β-cell dysfunction. Therefore, manipulation of miR-21 and miR-34a levels may potentially be beneficial to β cells. To study the effect of long-term alterations of miR-21 or miR-34a levels upon net β-cell number, we stably overexpressed miR-21 and knocked down miR-34a, and investigated essential cellular processes. MATERIALS AND METHODS: miRNA expression was manipulated using Lentiviral transduction of the β-cell line INS-1. Stable cell lines were generated, and cell death, NO synthesis, proliferation, and total cell number were monitored in the absence or presence of cytokines. RESULTS: Overexpression of miR-21 decreased net β-cell number in the absence of cytokines, and increased apoptosis and NO synthesis in the absence and presence of cytokines. Proliferation was increased upon miR-21 overexpression. Knockdown of miR-34a increased net β-cell number in the absence of cytokines, and reduced apoptosis and NO synthesis in the absence and presence of cytokines. Proliferation was decreased upon miR-34a knockdown. CONCLUSION: As overexpression of miR-21 increased proliferation, but also apoptosis and NO synthesis, the potential of miR-21 as a therapeutic agent to increase β-cell survival is doubtful. Knockdown of miR-34a slightly decreased proliferation, but as apoptosis and NO synthesis were highly reduced, miR-34a may be further investigated as a therapeutic target to reduce β-cell death and dysfunction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A pancreatic islet-specific microRNA regulates insulin secretion
Poy, M. N., Eliasson, L., Krutzfeldt, J., Kuwajima, S., Ma, X., MacDonald, P. E., Pfeffer, S., Tuschl, T., Rajewsky, N., Rorsman, P., et al. (2004) · Nature · doi:10.1038/nature03076 · Cited by 2,102 · cited 1×
“e27754-2 Islets Volume 6 differentiation,(9,10) regulation of expression of essential β-cellular transcription factors as well as insulin,(9) and regulation of insulin secretion.(10,11) Recently, miRNAs were shown to regulate β-cell apoptosis following exposure to fatty acids and cytokines.”
BackgroundTransactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis
Chang, T.-C., Wentzel, E. A., Kent, O. A., Ramachandran, K., Mullendore, M., Lee, K. H., Feldmann, G., Yamakuchi, M., Ferlito, M., Lowenstein, C. J., et al. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.010 · Cited by 2,010
Interleukin-1-receptor antagonist in type 2 diabetes mellitus
Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065213 · Cited by 1,798 · cited 1×
“Cytokine antagonists are under study as novel antidiabetic treatments.(5,6) MicroRNAs (miRNAs) are small noncoding ~22 nucleotide transcripts regulating protein expression by binding to complementary mRNA binding regions thereby targeting them for either degradation or translational inhibition.”
BackgroundSelf-citationMicroRNA-21 Targets the Tumor Suppressor Gene Tropomyosin 1 (TPM1)
Zhu, S., Si, M.-L., Wu, H., & Mo, Y.-Y. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m611393200 · Cited by 1,090
Sheedy, F. J., Palsson-McDermott, E., Hennessy, E. J., Martin, C., O'Leary, J. J., Ruan, Q., Johnson, D. S., Chen, Y., & O'Neill, L. A. J. (2010) · Nature Immunology · doi:10.1038/ni.1828 · Cited by 1,005
miR‐21: a small multi‐faceted RNA
Krichevsky, A. M., & Gabriely, G. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00556.x · Cited by 987
Iliopoulos, D., Jaeger, S. A., Hirsch, H. A., Bulyk, M. L., & Struhl, K. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.07.023 · Cited by 830
MicroRNA-21 Targets a Network of Key Tumor-Suppressive Pathways in Glioblastoma Cells
Papagiannakopoulos, T., Shapiro, A., & Kosik, K. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1305 · Cited by 705
PDGFRαα Signaling Is Regulated through the Primary Cilium in Fibroblasts
Schneider, L., Clement, C. A., Teilmann, S. C., Pazour, G. J., Hoffmann, E. K., Satir, P., & Christensen, S. T. (2005) · Current Biology · doi:10.1016/j.cub.2005.09.012 · Cited by 592
Inflammatory mediators and islet ?-cell failure: a link between type 1 and type 2 diabetes
Donath, M. Y., St�rling, J., Maedler, K., & Mandrup-Poulsen, T. (2003) · Journal of Molecular Medicine · doi:10.1007/s00109-003-0450-y · Cited by 422
Self-citationMicroRNA Expression Is Required for Pancreatic Islet Cell Genesis in the Mouse
Lynn, F. C., Skewes-Cox, P., Kosaka, Y., McManus, M. T., Harfe, B. D., & German, M. S. (2007) · Diabetes · doi:10.2337/db07-0175 · Cited by 351
Proliferation of sorted human and rat beta cells
Parnaud, G., Bosco, D., Berney, T., Pattou, F., Kerr-Conte, J., Donath, M. Y., Bruun, C., Mandrup-Poulsen, T., Billestrup, N., & Halban, P. A. (2007) · Diabetologia · doi:10.1007/s00125-007-0855-1 · Cited by 232 · cited 1×
“Additionally, when investigating altered proliferation and growth rates INS-1 cells provide an advantage, as detecting such alterations in primary β cells can be difficult due to their very low basal proliferation.(45,46) The current data however warrants the design of future experiments investigating the roles of miR…”
BackgroundSelf-citationDownregulation of Pdcd4 by mir-21 facilitates glioblastoma proliferation in vivo
Gaur, A. B., Holbeck, S. L., Colburn, N. H., & Israel, M. A. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor033 · Cited by 180
Loss of programmed cell death 4 induces apoptosis by promoting the translation of procaspase-3 mRNA
Eto, K., Goto, S., Nakashima, W., Ura, Y., & Abe, S.-I. (2012) · Cell Death & Differentiation · doi:10.1038/cdd.2011.126 · Cited by 64 · cited 1×
“An explanation for the lack of longterm protection of PDCD4 knockdown may be due to elevated apoptosis through decreased translational repression of procaspase 3 mRNA as suggested in.(34) We were not able to detect a reduction in PDCD4 mRNA levels (Fig.”
Background
Cited by
β-Cell MicroRNAs: Small but Powerful
Filios, S. R., & Shalev, A. (2015) · Diabetes · doi:10.2337/db15-0831 · Cited by 106
MicroRNA 21 targets BCL2 mRNA to increase apoptosis in rat and human beta cells
Sims, E. K., Lakhter, A. J., Anderson-Baucum, E., Kono, T., Tong, X., & Evans-Molina, C. (2017) · Diabetologia · doi:10.1007/s00125-017-4237-z · Cited by 100
Ibrahim, S., Johnson, M., Stephens, C. H., Xu, J., Moore, R., Mariani, A., Contreras, C., Syed, F., Mirmira, R. G., Anderson, R. M., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101289 · Cited by 18
Metadata
- Authors
- Backe, M. B., Novotny, G. W., Christensen, D. P., Grunnet, L. G., & Mandrup-Poulsen, T.
- Venue
- Islets
- Publisher
- Informa UK Limited
- Published
- 2014-01-14
- Volume
- 6
- Issue
- 1
- Pages
- e27754
- ISSN
- 1938-2014 (ISSN-L)
- 1938-2022
- OpenAlex
- W2102045400
- Cited by
- 44
- References
- 14
- FWCI
- 3.29
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.